

## The risk of mental illness in people living with HIV in the UK

Gooden, Tiffany; Gardner, Michael; Wang, Jingya; Chandan, Joht; Beane, Abi ; Haniffa, Rashan ; Taylor, Stephen; Greenfield, Sheila; Manaseki-Holland, Semira; Thomas, G Neil; Nirantharakumar, Krishnarajah

DOI:

[10.1016/S2352-3018\(21\)00319-2](https://doi.org/10.1016/S2352-3018(21)00319-2)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Gooden, T, Gardner, M, Wang, J, Chandan, J, Beane, A, Haniffa, R, Taylor, S, Greenfield, S, Manaseki-Holland, S, Thomas, GN & Nirantharakumar, K 2022, 'The risk of mental illness in people living with HIV in the UK: a propensity-score matched cohort study', *The Lancet HIV*, vol. 9, no. 3, pp. e172-e181. [https://doi.org/10.1016/S2352-3018\(21\)00319-2](https://doi.org/10.1016/S2352-3018(21)00319-2)

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1 The risk of mental illness in people living with HIV in the UK:  
2 a propensity-score matched cohort study

3

4 Author names:

5

6 Tiffany E Gooden, Mike Gardner, Jingya Wang, Joht S Chandan, Abi Beane,  
7 Rashan Haniffa, Stephen Taylor, Sheila Greenfield, Semira Manaseki-Holland, G  
8 Neil Thomas, Krishnarajah Nirantharakumar

9

10 Author affiliations and addresses:

11

12 Institute for Applied Health Research, College of Medical and Dental Sciences,  
13 University of Birmingham, Birmingham, United Kingdom (Ms Tiffany E Gooden MPH,  
14 Dr Mike Gardner PhD, Dr Jingya Wang PhD, Dr Joht S Chandan MBBS, Dr Stephen  
15 Taylor PhD, Professor Sheila Greenfield PhD, Dr Semira Manaseki-Holland PhD,  
16 Professor G Neil Thomas PhD, Professor Krishnarajah Nirantharakumar MD)

17 Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand (Dr Abi Beane  
18 PhD, Professor Rashan Haniffa PhD)

19

20 Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (Dr Abi  
21 Beane PhD, Professor Rashan Haniffa PhD)

22 Department of Infection and Immunology, University Hospitals Birmingham,  
23 Birmingham, United Kingdom (Dr Stephen Taylor PhD)

24

25

26 Corresponding authors:

27 G Neil Thomas, Institute for Applied Health Research, University of Birmingham,  
28 Edgbaston, Birmingham B15 2TT, United Kingdom. E-mail:  
29 G.N.Thomas@bham.ac.uk

30

31 Semira Manaseki-Holland, Institute for Applied Health Research, University of Birmingham,  
32 Edgbaston, Birmingham B15 2TT, United Kingdom. E-mail:  
33 S.ManasekiHolland@bham.ac.uk

34

35

36 Keywords: comorbidity, HIV, depression, anxiety, severe mental illness

## 37 Abstract

38

### 39 Background

40 Prevalence of mental illness is higher in people living with HIV (PLWH) compared to  
41 the general population, but the incidence of composite mental illness and its  
42 components is unclear. We aimed to identify the risk of incident mental illness along  
43 with individual conditions of depression, anxiety and severe mental illness (SMI) in  
44 PLWH in the UK.

### 45 Methods

46 Data for this population-based cohort was extracted from the IQVIA Medical  
47 Research Database, a nationally representative UK-based database of primary care  
48 electronic health records. We included adult ( $\geq 18$ y) PLWH, matched with people  
49 without HIV using propensity-score matching (1:1 ratio). The primary outcome was  
50 composite mental illness comprising a diagnosis of depression, anxiety or SMI.  
51 Secondary outcomes were individual mental health conditions. Cox proportional  
52 hazard regression models were used to compare the risk of each outcome between  
53 people with and without HIV. Each model excluded those with the outcome at  
54 baseline. Study period was from January 2000 to January 2020.

### 55 Findings

56 Of 7167 PLWH without mental illness at baseline, 586 developed a mental illness  
57 (Incidence Rate (IR) 19.6 per 1000 person-years) compared with 418 of the 7167  
58 people without HIV (IR 12.1 per 1000 person-years), resulting in an adjusted hazard  
59 ratio [aHR] of 1.63 (95% CI 1.44, 1.85). PLWH had higher IRs for depression (15.4  
60 per 1000 person-years), anxiety (7.2 per 1000 person-years) and SMI (1.6 per 1000  
61 person-years) compared to people without HIV (7.9, 5.0 and 0.6 per 1000 person-  
62 years, respectively), translating to aHRs of 1.94 (95% CI 1.68, 2.24) for depression,  
63 1.38 (95% CI 1.15, 1.66) for anxiety and 2.18 (95% CI 1.41, 3.39) for SMI.

### 64 Interpretation

65 PLWH have an increased risk for developing composite mental illness, depression,  
66 anxiety and SMI when compared to people without HIV. PLWH should be regularly  
67 screened for mental illness; however, there is a strong need to improve prevention of  
68 mental illness in PLWH and for more outreach programmes to ensure no PLWH are  
69 being underdiagnosed.

### 70 Funding

71 This study has no funding to report.

## 72 Research in context

73

### 74 Evidence before this study

75 Pubmed was systematically searched from database inception to 26<sup>th</sup> August 2021. Key  
76 terms were used such as (“HIV” AND “inciden\*\*”) AND (“depression” OR “anxiety” OR  
77 “schizophrenia” OR “bipolar” OR “psychosis”). No restrictions to the search were applied. All  
78 citations were assessed for studies that report the incidence of the aforementioned mental  
79 health conditions in people living with HIV (PLWH). Most studies that investigated the risk of  
80 mental illness in adult PLWH reported incidence rates with no comparison group. Only four  
81 studies were found to use comparison groups, two were conducted in the USA, one in South  
82 Korea and one in Denmark with follow-up times ranging from 1 to 17 years. The latter two  
83 were population-based. The South Korean study investigated the risk of depression only and  
84 was the only study to use a matched comparison group (by age and sex); however, they  
85 excluded those with a noncommunicable disease, did not control for alcohol use and  
86 neglected to report the exact incident rate ratio (IRR). One of the USA studies used a cohort  
87 of men who have sex with men from four major cities (thus excluded females and PLWH in  
88 rural areas) and reported a higher risk of depression in PLWH with or without sleep  
89 disturbances compared to people without HIV with or without sleep disturbances. The other  
90 USA study used a cohort of military members which were predominantly male (97%) and  
91 reported a significant increased risk of depression (IRR 2·9), bipolar disorder (IRR 3·3),  
92 anxiety (IRR 2·0) and psychosis/schizophrenia (IRR 6·2). The Danish study also reported an  
93 increased risk for schizophrenia (IRR 4·1) and psychosis (IRR 7·6).

### 94 Added value of this study

95 To our knowledge, this is the first study to report the risk of incident composite mental illness  
96 (comprised of depression, anxiety and severe mental illness including bipolar disorder,  
97 schizophrenia and psychosis) in PLWH compared to a matched comparison group of people  
98 without HIV. Additionally, this will be the first population-based study to report the risk of  
99 incident anxiety and severe mental illness using a matched comparison group. Between  
100 2000 and 2020, we used a large UK primary care dataset representative of the UK  
101 population to report a 63% increased risk for incident composite mental illness, 94%  
102 increased risk for depression, 38% increased risk for anxiety and a 2-fold risk for severe  
103 mental illness in PLWH compared to people without HIV. Mental illness impacts wellbeing  
104 and quality of life in the general population, but in PLWH, it also impacts adherence to  
105 antiretroviral therapy and retention in care. The consequences of this is a weakened immune  
106 system and increased viral load which increases the risk of onward transmission of HIV and  
107 PLWH's risk for coinfections, AIDS and death. Our study highlights a large burden of mental  
108 illness among PLWH compared to those without HIV in the UK. Given the personal and  
109 public health ramifications of this, these findings are vital for policy and practice in the UK  
110 and other high-income countries.

### 111 Implications of all the available evidence

112 In combination with existing evidence, our findings improve the global understanding of the  
113 increased burden of mental illness in PLWH compared to people without HIV. Given the  
114 strengths of our study, our results are not only important for the UK, but also other high-  
115 income countries. Our findings support regular screening for mental illness in PLWH, but  
116 also highlights the need to improve prevention and ensure all PLWH are being reached by  
117 the existing screening programmes.

## 118 Introduction

119

120 People living with HIV (PLWH) often experience multiple coexisting conditions.<sup>1</sup>  
121 Mental illness is among the most common comorbidity in PLWH, including  
122 depression, anxiety and severe mental illness (SMI) (such as psychoses,  
123 schizophrenia and bipolar disorder).<sup>1</sup> In the UK, the prevalence of depression and  
124 anxiety in PLWH has been reported to range from 27-47% and 22-49%,  
125 respectively.<sup>2</sup> For PLWH, comorbid mental illness is associated with non-adherence  
126 to antiretroviral therapy (ART) and retention in HIV care<sup>3</sup> which can result in a loss of  
127 virologic control and worsening immune suppression. In turn, this increases the risk  
128 of onward transmission of HIV, the development of opportunistic infections, AIDS  
129 and death. Additional impacts of mental illness in PLWH include unemployment,  
130 increased hospitalisation, lowered quality of life and further comorbidities.<sup>1,4,5</sup> Thus,  
131 mental illness in PLWH is an important personal and public health issue.

132 Due to complex biological and psychosocial factors, a bidirectional relationship  
133 between mental illness and HIV is presumed.<sup>6,7</sup> High-risk behaviours such as  
134 injecting drug use, sex work, unprotected sex and multiple sexual partners are  
135 variable among people with mental illness; however, some evidence suggests that  
136 people with mental illness are more likely to engage in such behaviours and  
137 therefore more likely to be exposed to and become infected with HIV.<sup>8,9</sup> Conversely,  
138 potential drivers for developing mental illness in PLWH include persistent stress,  
139 stigma, discrimination, social isolation, drug-related side effects and neurological  
140 effects from the HIV infection.<sup>7</sup> Such negative experiences may support the  
141 development of mental illness in PLWH or exacerbate the effects of pre-existing  
142 psychosocial factors associated with HIV exposure.<sup>7</sup>

143 Many studies that have investigated the risk of incident mental illness in PLWH suffer  
144 from major limitations. One USA study reported more than a 2-fold risk for  
145 depression, anxiety and SMI; though, the sample comprised 97% male PLWH in the  
146 military and a non-matched comparison group.<sup>10</sup> Another USA study reported a  
147 higher risk for depression in PLWH compared to a non-matched comparison group  
148 which comprised only men who have sex with men (MSM) from urban settings.<sup>11</sup> A  
149 population-based Danish study reported a 7-fold risk for psychosis and 4-fold risk for  
150 schizophrenia;<sup>6</sup> however, a non-matched comparison group was used. The only  
151 population-based study to use a matched comparison group was conducted in South  
152 Korea; they reported an increased risk for depression (exact risk not reported);  
153 however, individuals with any noncommunicable disease (i.e. not only mental illness)  
154 at baseline were excluded and alcohol use was not controlled for.<sup>12</sup> No study has  
155 reported the risk of composite mental illness. Additionally, no study has investigated  
156 the risk of incident mental illness in PLWH within the UK where healthcare is free  
157 and access to HIV and mental healthcare is largely available. In the UK, HIV-specific  
158 services (for example, ART prescriptions and viral load testing) are available at HIV  
159 clinics. If mental health symptoms are identified and are not ART-related, these  
160 individuals are referred to their general practitioner or signposted to self-refer to  
161 mental health services as part of the National Health Service (NHS). Some larger  
162 HIV clinics have specialised psychological support; though this is limited. When a

163 general practitioner suspects or diagnosis mental illness, they too may signpost  
164 PLWH to self-refer to NHS mental health services for specialised psychology or  
165 psychiatry care. General practitioners can prescribe medication for depression and  
166 anxiety if necessary. PLWH can also access mental health support from non-  
167 governmental organisations available across the UK that offer free services such as  
168 helplines, peer support and tips for improving mental wellbeing.

169 To enable the development of effective interventions for reducing mental illness in  
170 PLWH, it is important to improve global understanding of whether PLWH experience  
171 an increased burden of mental illness compared to people without HIV and whether  
172 the risk differs across key groups of PLWH. We conducted the first population-based  
173 matched cohort study aimed at investigating the risk of incident composite mental  
174 illness in PLWH compared to people without HIV in the UK. Additionally, we aimed to  
175 report the risk of depression, anxiety and SMI in PLWH.

176

## 177 **Methods**

### 178 **Study design and data source**

179 Data for this population-based matched cohort study was derived from the IQVIA  
180 Medical Research Database (IMRD)-UK (formally known as The Health  
181 Improvement Network (THIN)). IMRD-UK is a nationally representative UK-based  
182 database of primary care electronic records.<sup>13</sup> Compared to external statistics and  
183 individual studies, diagnoses, lifestyle and anthropometric data within IMRD-UK is  
184 considered well-recorded and accurate.<sup>14,15</sup> Such data is recorded as Read codes, a  
185 hierarchical clinical coding system utilised in the UK since 1985 and checked for  
186 accuracy every 12 months.<sup>16</sup> To reduce the risk of under-recording of conditions and  
187 improve data quality, primary care practices were included 12 months after they  
188 installed electronic medical records and from the practice's acceptable mortality  
189 recording date. The study period was from 1st January 2000 to 1st January 2020.

190 Anonymised data were used throughout the study. Studies using IMRD-UK received  
191 initial ethical approval from the NHS South-East Multicentre Research Ethics  
192 Committee and the IQVIA Scientific Review Committee approved the study protocol  
193 (reference: 20SRC067).

### 194 **Procedures**

195 Individuals were eligible for the study if they were aged 18 years or older and had  
196 been registered with a primary care practice for at least 12 months (for data quality  
197 purposes). A Read code indicative of HIV infection such as HIV positive (e.g. code  
198 43C.11), AIDS (e.g. code A788.00) or any cancers (e.g. code A789500) or  
199 coinfections (e.g. code A789300) resulting from HIV infection were required for  
200 PLWH whereas the absence of such Read codes were required for possible controls  
201 (supplemental table 1 page 2). For each outcome, PLWH and controls with the  
202 outcome of interest at baseline were excluded prior to propensity-score matching  
203 (PSM) and analysis.

204 Matching was done in two stages. Controls were extracted from IMRD-UK through  
205 exact matching to PLWH (20:1 ratio) based on region, age within 1 year, sex,  
206 ethnicity and deprivation. To match on further characteristics, PLWH were then  
207 matched to one of the extracted controls (1:1 ratio) using propensity scores  
208 calculated from logistic regression models with a caliper width of 0.2. The balance of  
209 matching was tested by comparing the propensity score density before and after  
210 matching and the standard mean difference (SMD) of propensity scores between the  
211 two groups.

212 The index date for PLWH was the date of the first Read code related to an HIV  
213 diagnosis for incident infections (diagnosed during the study period) and the date  
214 they became eligible for the study for those with a previous recorded Read code  
215 related to HIV (prevalent infections); controls were given the same index date as  
216 their matched counterpart. The exit date for each individual was the earliest date of  
217 the: outcome event, transfer date, last medical record available, death date or study  
218 end date. Individuals were followed-up prospectively from their index date to their  
219 exit date.

220 Covariates for PSM and for adjusted analyses were decided a priori based on  
221 biological and clinical importance and data availability.<sup>6,17</sup> These included the  
222 following covariates measured at the index date for each participant: age and index  
223 year as continuous variables and sex, ethnicity, smoking status, body mass index  
224 (BMI), substance abuse status, social deprivation, geographical region and status of  
225 existing cardiometabolic diseases (cardiovascular disease, hypertension and  
226 diabetes) as categorical variables. Substance abuse was a binary variable  
227 comprising those with or without a Read code indicative of alcohol, cocaine or other  
228 substance misuse (including injecting drug use). Townsend quintiles were used for  
229 social deprivation, which are based on employment status, household overcrowding  
230 and house/car ownership.<sup>18</sup> When investigating the risk for depression, existing  
231 anxiety and SMI were also entered as covariates for PSM and adjusted analyses; for  
232 investigating the risk of anxiety, existing depression and SMI were entered; and for  
233 investigating the risk of SMI, existing depression and anxiety were entered.

## 234 **Outcomes**

235 The primary outcome was composite mental illness, defined through Read codes  
236 (composite measure of depression, anxiety and SMI; each defined in supplemental  
237 table 1 page 2). Diagnoses are shared with the person's general practice in the  
238 majority of cases unless the person dissents to the sharing of their data. Secondary  
239 outcomes were the individual mental health conditions of depression, anxiety and  
240 SMI. We expected the coding of depression and SMI to be well coded as they form  
241 part of the Quality Outcome Framework which are performance indicators linked to  
242 general practice payments in the UK.<sup>19</sup> Additionally, we expected anxiety to be well  
243 coded as previous studies have demonstrated similar prevalence in IMRD-UK  
244 compared with national survey data.<sup>20</sup> For each outcome, only the first diagnosis was  
245 used; subsequent diagnoses were not considered.

## 246 **Statistical methods**

247 We used descriptive statistics to report baseline characteristics, presenting means  
248 for continuous variables and proportions for categorical variables. Crude and  
249 adjusted hazard ratios (aHRs) with their corresponding 95% CIs were calculated  
250 using Cox proportional hazard regression models. Using multinomial logistic  
251 regression, twenty multiple imputations by chained equations were undertaken to  
252 impute missing data for smoking, BMI, deprivation and ethnicity after matching; all  
253 variables used within the adjusted Cox regressions were entered in the regression.  
254 Due to the high proportion of missing ethnicity data, a missing indicator was added to  
255 adjusted regressions to control for any non-observable confounders that may  
256 contribute to the non-randomness of missing ethnicity data.<sup>21</sup> All statistical tests were  
257 two-tailed and  $P < 0.05$  was considered statistically significant. All analyses were  
258 conducted in Stata 14.0 (College Station, Texas, USA).

259 Sub-group analysis was undertaken to identify the risk of mental illness across  
260 various groups of PLWH compared to their HIV-negative counterparts. Sub-groups  
261 were determined a priori based on existing literature<sup>17</sup> and included the following:  
262 age (<40 and  $\geq 40$  years old), sex (male and female), index year (2000-2009 and  
263 2010-2019), deprivation level (least deprived/lower two quintiles and most  
264 deprived/upper two quintiles), ethnicity (White and non-White), BMI (<30 and  $\geq 30$   
265 kg/m<sup>2</sup>), smoking status (current/ex-smoker and never smoked) and substance abuse  
266 status (substance abuser and non-substance abuser). Cox proportional hazard  
267 regression models were used to present aHRs with 95% CIs for each sub-group  
268 between people with and without HIV.

269 To test the robustness of PSM, we applied bounding and simulation sensitivity  
270 analyses as suggested by Becker<sup>22</sup> and Nannicini<sup>23</sup>, respectively. To control for  
271 potential bias of including prevalent HIV infections, a sensitivity analysis was  
272 conducted among incident HIV infections only for each outcome. For the primary  
273 outcome, a sensitivity analysis was conducted that excluded those with missing  
274 ethnicity data to check whether the high proportion of missingness introduced bias.  
275 For each secondary outcome, a sensitivity analysis was undertaken that excluded  
276 individuals with a baseline diagnosis of any mental illness to check for potential bias.

## 277 **Role of the funding source**

278 There was no funding source for this study.

279

## 280 **Results**

281

282 Data was available for 15,837,846 people across all available general practices  
283 (figure 1). After applying the appropriate study period, age and data quality  
284 requirements, 9233 PLWH were identified and matched with 172,860 possible  
285 controls. Exclusion of those with mental illness at baseline left 7167 eligible PLWH  
286 for investigating the primary outcome; they were then matched with 7167 eligible  
287 controls. We included 7612 depression-free PLWH matched with 7612 depression-  
288 free controls for investigating the risk of depression, 8562 anxiety-free PLWH



289 matched with 8562 anxiety-free controls for the anxiety outcome and 9040 SMI-free  
290 PLWH matched with 9040 SMI-free controls for the SMI outcome.

291 No difference was found between density curves or SMDs after PSM; therefore,  
292 people with and without HIV were similar in age, sex, ethnicity, deprivation, BMI,  
293 smoking status and substance abuse for each outcome (table 1). For the primary  
294 outcome, the mean follow-up years were only slightly higher for people without HIV  
295 (4.8 years) than PLWH (4.2 years) (table 2). During follow-up, there were 586 and  
296 418 diagnoses of mental illness in people with and without HIV, respectively. This  
297 resulted in an IR of 19.6 per 1000 person-years for PLWH and 12.1 for people  
298 without HIV. IRs for individual mental health conditions were also higher for PLWH  
299 compared to people without HIV (table 2).

300 After fully adjusting the models, PLWH had a 63% elevated risk for incident  
301 composite mental illness (95% CI 1.44, 1.85) (table 2). PLWH had a 94% increased  
302 risk for depression (95% CI 1.68, 2.24), 38% increased risk for anxiety (95% CI 1.15,  
303 1.66) and a 2-fold risk for SMI (aHR 2.18, 95% CI 1.41, 3.39). When prevalent cases  
304 were removed from the model, PLWH remained at an increased risk for composite  
305 mental illness and depression whereas the effect size for anxiety and SMI were  
306 reduced (supplemental table 2 page 14). The risk of depression, anxiety and SMI  
307 were broadly similar when those with any mental illness at baseline were excluded  
308 (supplemental table 3 page 15). Removing those with missing ethnicity data did not  
309 impact the effect size for composite mental illness (data not shown).

310 Table 3 provides aHRs and 95% CIs for each outcome across sub-groups. Here we  
311 summarise the findings. Compared to males without HIV, male PLWH had an  
312 increased risk for composite mental illness, depression, anxiety and SMI. Aside from  
313 SMI, effect sizes for males were significantly larger compared to females. Female  
314 PLWH were not at a higher risk for any condition. Irrespective of age, PLWH had a  
315 heightened risk for all outcomes. Compared to White people without HIV, White  
316 PLWH had an increased risk for composite mental health, depression and anxiety.  
317 Non-White PLWH were only at a heightened risk for depression. The least and most  
318 deprived PLWH were at an increased risk for composite mental illness, depression  
319 and anxiety. Only the most deprived PLWH had a higher risk for SMI; though, the  
320 effect size for the least deprived was 4-fold. Obese PLWH only had an increased risk  
321 for depression. Non-obese PLWH had an increased risk for all outcomes.  
322 Regardless of smoking status, PLWH had a higher risk for composite mental illness,  
323 depression and SMI. Only PLWH that were current/ex-smokers had a higher risk for  
324 anxiety. PLWH substance abusers did not have an increased risk for any outcome.  
325 Non-substance abusers had an increased risk for all outcomes. PLWH had an  
326 elevated risk for composite mental illness and depression in the earlier (2000-2009)  
327 and later (2010-2019) index years. PLWH only had an increased risk for anxiety in  
328 the later index years and for SMI in the earlier index years.

329

## 330 Discussion

331

332 As access to ART continues to improve globally, ensuring optimal mental health will  
333 be imperative for healthy aging in PLWH. Understanding the relationship between  
334 HIV infection and mental illness will allow for improved interventions for prevention  
335 and treatment. To our knowledge, this is the first study to investigate the  
336 development of composite mental illness in PLWH compared to people without HIV.  
337 Using a population-based matched cohort derived from medical records, our findings  
338 demonstrates that PLWH are at a heightened risk for developing composite mental  
339 illness and individual conditions of depression, anxiety and SMI. The risk differed  
340 across sub-groups, most notably with sex. However, the risk for composite mental  
341 illness was elevated for PLWH irrespective of age, deprivation and smoking status,  
342 and the risk did not change over the 20-year study period.

343 Our results for the risk of depression, anxiety and SMI are in line with existing  
344 evidence.<sup>6,10-12</sup> However, our study may not be directly comparable due to  
345 differences in setting, sample characteristics, comparison group used and methods  
346 for classifying the exposure (i.e. HIV) and outcomes. Mental illness is detrimental to  
347 the wellbeing and quality of life of PLWH<sup>4</sup> and also poses a public health concern.  
348 PLWH with depression are 14% less likely to use ART than PLWH without  
349 depression which increases the risk of AIDS-defining infections and secondary  
350 transmission of HIV.<sup>3</sup> Thus, our findings of an 94% increased risk of depression in  
351 PLWH highlights a major implication for incident HIV and the healthy ageing and  
352 clinical care of PLWH in the UK. Current guidelines from the British HIV Association  
353 recommend annual screening for new or changes in mental health symptoms in  
354 PLWH,<sup>24</sup> of which our findings support. This could mean that PLWH may be more  
355 likely to be screened and diagnosed with mental illness compared with people  
356 without HIV. However, Public Health England reports that 75% of PLWH in the UK  
357 have unmet need for receiving help regarding isolation and loneliness and 10% of  
358 PLWH avoid accessing healthcare due to stigma and other reasons.<sup>25</sup> Therefore, it is  
359 also possible that PLWH are less likely to be screened and diagnosed with mental  
360 illness. Annual screening may not be sufficient for identifying all PLWH suffering from  
361 mental illness, particularly given the impact of mental illness on retention in care.

362 Considering the similarities of demographic and lifestyle characteristics between  
363 people with and without HIV in our study, PLWH's increased risk of mental illness  
364 appears to be from biological or psychosocial factors or a combination of the two.  
365 Persistent immune activation caused by HIV infection leads to the release of pro-  
366 inflammatory cytokines and central nervous system disturbances, potentially  
367 contributing to the pathophysiology of depression and schizophrenia.<sup>26-28</sup> Further to  
368 this, PLWH face significant social isolation due to stigma perpetuated by negative  
369 attitudes, behaviours and discrimination from society, community members and  
370 healthcare professionals.<sup>29</sup> HIV-related stigma can induce the development of mental  
371 illness, particularly when other risk factors are present.<sup>7,29</sup> HIV is often inextricably  
372 intertwined with social and psychological adversities. For instance, PLWH are more  
373 likely to be socially disadvantaged and suffer from financial, employment, housing  
374 and food insecurities, inadequate social networks and trauma caused by sexual or  
375 physical abuse.<sup>7,8</sup> Indeed, nearly a quarter of our sample were considered most  
376 deprived. Such circumstances are associated with mental illness in the general

377 population;<sup>20</sup> though, this syndemic with HIV creates barriers to accessing and  
378 utilising resources for mitigating the further psychological effects of living with HIV.<sup>8</sup>  
379 The biological mechanisms behind the increased risk of mental illness in PLWH  
380 should be further investigated to inform the development of pharmacological  
381 interventions. However, to address the complex relationship between mental illness  
382 and HIV-related psychosocial factors, stigma must be addressed and eliminated  
383 within the community and in healthcare settings. Furthermore, social and economic  
384 policy must be evaluated, improved and applied to conduce large-scale prevention of  
385 mental illness in this vulnerable population.

386 We found that male PLWH have a 2-fold risk for composite mental illness when  
387 compared to males without HIV, and this was significantly higher than the risk for  
388 female PLWH. Sexual orientation is not well recorded in primary care<sup>30</sup> though it is  
389 plausible that the proportion of MSM is higher within PLWH,<sup>8</sup> a group more targeted  
390 from various organisations and therefore more likely to be referred for mental health  
391 screening compared to MSM without HIV. The proportion of MSM may also be lower  
392 in people without HIV than in PLWH. However, MSM are often more socially  
393 disadvantaged and experience more discrimination, stigma and inequalities, thus  
394 more likely to develop mental illness.<sup>8</sup> Interestingly, White, non-obese and non-  
395 substance abusers had an increased risk for composite mental illness whilst non-  
396 White, obese and substance abusers did not. The latter three groups are more  
397 susceptible to social and economic inequalities and subsequently to mental illness;  
398 however, these groups have lower diagnoses and treatment rates in the UK.<sup>20</sup> Thus,  
399 our sub-group results may provide an indication that these groups of PLWH are  
400 vulnerable to being underdiagnosed rather than an indication of no risk of developing  
401 mental illness. This should be verified in future research.

402 Despite the strengths of using a population-based matched cohort and 20-year  
403 follow-up period, there are some limitations to mention. The main limitation is the  
404 lack of ART, CD4 and viral load data which is managed in HIV clinics rather than  
405 general practice. Between 2003 and 2015, Efavirenz was one of the most commonly  
406 prescribed antiretroviral agents, a drug associated with central nervous system and  
407 mood disturbances.<sup>31</sup> Such mood disturbances may have been recorded as a mental  
408 health condition and not as a drug-related phenomenon. Without ART data, it is  
409 unclear how the use of Efavirenz may have impacted our results. Transmission  
410 mode nor sexual orientation was available in our dataset which can be used to  
411 identify key populations of PLWH.<sup>8</sup> Nonetheless, our sub-group analysis on sex and  
412 substance abuse provides a valuable insight. Poorly recorded ethnicity data poses  
413 another limitation; however, we took a number of steps to limit and understand the  
414 potential bias caused. Our results are likely only generalisable to other high-income  
415 countries due to differences in cultural, environmental, societal and healthcare  
416 challenges with lower-income countries. Some of our sensitivity and sub-group  
417 analyses suffered from limited power and results should be interpreted with caution.  
418 The sensitivity analysis suffers from a reduced follow-up time which may impact  
419 results for conditions with long duration between symptom onset and diagnosis. It is  
420 possible that residual confounders between the groups could still exist after PSM;  
421 however, our sensitivity analyses indicated that it is unlikely that an unobserved

422 confounder would have largely impacted our results. Lastly, although the prevalence  
423 of HIV in IMRD-UK is close to national estimates (0.11% vs 0.15%, respectively),<sup>32</sup> it  
424 is possible that some PLWH may dissent to the sharing of their HIV diagnosis with  
425 their general practice.

426 We provide first-time evidence that PLWH are at an increased risk of developing  
427 composite mental illness compared to people without HIV. PLWH had a 63%  
428 increased risk for incident composite mental illness, a 94% increased risk for  
429 depression, a 38% increased risk for anxiety and a 2-fold risk for SMI. Our findings  
430 support current UK guidelines to annually screen for mental illness in PLWH;  
431 however, future research should investigate whether screening is sufficient for  
432 identifying all PLWH at risk for mental illness and how to reach groups of PLWH at  
433 risk for underdiagnosis. Our findings highlight the need to determine effective  
434 interventions for reducing mental illness in PLWH, including pharmacological  
435 interventions, reducing stigma and improving social and economic policies for  
436 addressing the complex psychosocial factors associated with mental illness among  
437 PLWH.

438

439

440

## 441 Contributors

442 This study contributed to the PhD thesis for the main author TEG. The following  
443 authors contributed to the conceptualisation of the study: TEG, MG, JW, AB, RH,  
444 GNT and KN. TEG, MG, JW, KN and GNT developed the protocol for the study.  
445 TEG, MG and JW completed the ethics application. TEG completed the literature  
446 search, drafted the manuscript and conducted all analyses with guidance from JSC  
447 and ST. JW validated the data. Supervisors of the study were SG, SMH, GNT and  
448 KN. All authors reviewed and critically appraised the manuscript revision, approved  
449 the final version for submission, had full access to all the data in this study, and had  
450 responsibility for the decision to submit for publication.

## 451 Funding

452 There is no funding to declare in this study.

## 453 Declaration of Interests

454 All authors have completed the ICMJE uniform disclosure form at  
455 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for  
456 the submitted work, no financial relationships with any organisations that might have  
457 an interest in the submitted work in the previous three years, no other relationships  
458 or activities that could appear to have influenced the submitted work.

459

## 460 Data sharing

461 IMRD-UK data governance does not allow us to share individual patient data, and  
462 therefore, only metadata are presented. Researchers may apply for individual patient  
463 data access at <https://www.iqvia.com/solutions/real-world-value-and-outcomes>  
464 (contact tab).

## References

1. De Francesco D, Sabin CA, Reiss P. Multimorbidity patterns in people with HIV. *Curr Opin HIV AIDS*. 2020;**15**:110-7.
2. Chavonda M, Aldhouse N, Kroes M, Wild L, Robinson C, Smith A. Systematic review of the prevalence of psychiatric illness and sleep disturbance as co-morbidities of HIV infection in the UK. *Int J STD AIDS*. 2018;**29**:704-13.
3. Tao J, Vermund SH, Qian H-Z. Association between depression and antiretroviral therapy use among people living with HIV: a meta-analysis. *AIDS Behav*. 2018;**22**:1542-50.
4. Bagheri Z, Taheri M, Motazedian N. The impacts of depression and anxiety on quality of life among patients with HIV/AIDS and their spouses: testing dyadic dynamics using the actor-partner interdependence model. *AIDS Care*. 2019;**31**:1500-8.
5. Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. *Lancet HIV*. 2014;**1**:e32-e40.
6. Helleberg M, Pedersen MG, Pedersen CB, Mortensen PB, Obel N. Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark. *Lancet HIV*. 2015;**2**:e344-e50.
7. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. *Curr Psychiatry Rep*. 2015;**17**:530.
8. UNAIDS. 2020 Global AIDS Update. Seizing the moment, tackling entrenched inequalities to end epidemics. UNAIDS; 2020.
9. Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. *Clin Psychol Rev*. 2005;**25**:433-57.
10. Mirza RA, Eick-Cost A, Otto JL. The risk of mental health disorders among US military personnel infected with human immunodeficiency virus, active component, US Armed Forces, 2000-2011. Armed forces health surveillance center silver spring md; 2012.
11. Irwin MR, Archer G, Olmstead R, Brown TT, Teplin LA, Patel SR, et al. Increased risk of depression in non-depressed HIV infected men with sleep disturbance: prospective findings from the Multicenter AIDS Cohort Study. *EBioMedicine*. 2018;**36**:454-60.
12. Kim JH, Noh J, Kim W, Seong H, Kim JH, Lee WJ, et al. Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea. *HIV Med*. 2021.
13. IQVIA. U EMR - IQVIA Medical Reserach Data. Improving patient outcomes with evidence-based research: IQVIA; 2020. <https://www.iqvia.com/library/fact-sheets/uk-emr-iqvia-medical-research-data> (accessed 08 Sept 2021).
14. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf* 2007;**16**:393-401.
15. Blak B, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. *J Innov Health Inform*. 2011;**19**:251-5.

16. Booth N. What are the read codes? *Health libraries review*. 1994;**11**:177-82.
17. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. *AIDS (London, England)*. 2019;**33**:1411.
18. Yousaf S, Bonsall A. UK Townsend Deprivation Scores from 2011 census data. Economic and Social Research Council; 2017.
19. NHS Digital. Quality and Outcomes Framework (QOF) business rules v42 2019-2020 baseline release: NHS Digital. <https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/quality-and-outcomes-framework-qof/quality-and-outcome-framework-qof-business-rules/quality-and-outcomes-framework-qof-business-rules-v42-2019-2020-baseline-release> (accessed 08 Sept 2021).
20. McManus S, Bebbington P, Jenkins R, Brugha T. Mental health and wellbeing in England: Adult psychiatric morbidity survey 2014. 2016. NHS Digital: Leeds; 2016.
21. Sholle ET, Pinheiro LC, Adekkanattu P, Davila III MA, Johnson SB, Pathak J, et al. Underserved populations with missing race ethnicity data differ significantly from those with structured race/ethnicity documentation. *J Am Med Inform Assoc*. 2019;**26**:722-9.
22. Becker SO, Caliendo M. Sensitivity analysis for average treatment effects. *Stata J*. 2007;**7**:71-83.
23. Nannicini T. Simulation-based sensitivity analysis for matching estimators. *Stata J*. 2007;**7**:334-50.
24. Angus B, Brook G, Awosusi F, Barker G, Boffito M, Das S, et al. BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals. British HIV Association; 2019.
25. Nash S, Desai S, Croxford S, Guerra L, Lowndes C, Connor N, et al. Progress towards ending the HIV epidemic in the United Kingdom: 2018 report. London: Public Health England; 2018.
26. Köhler C, Freitas T, Maes Md, De Andrade N, Liu C, Fernandes B, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatr Scand*. 2017;**135**:373-87.
27. Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. *Schizophr Bull*. 2018;**44**:973-82.
28. Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC. C-reactive protein and depression in persons with human immunodeficiency virus infection: the Positive Living with HIV (POLH) Study. *Brain Behav Immun*. 2014;**42**:89-95.
29. Rueda S, Mitra S, Chen S, Gogolishvili D, Gliberman J, Chambers L, et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. *BMJ Open*. 2016;**6**:e011453.
30. Lau F, Antonio M, Davison K, Queen R, Devor A. A rapid review of gender, sex, and sexual orientation documentation in electronic health records. *J Am Med Inform Assoc*. 2020;**27**:1774-83.
31. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). *HIV Med*. 2014;**15**:1-85.
32. Public Health England. Prevalence of HIV infection in the UK in 2018. England: Public Health England; 2019.